Barinthus Biotherapeutics plc. 8-K

What Happened

• Barinthus Biotherapeutics plc (BRNS) filed a Form 8-K on March 31, 2026 (Item 5.02) announcing that Gemma Jones, who provides services to the company as an employee of CFGI and serves as the company’s principal accounting officer, notified the company on March 27, 2026 that she will step down effective April 30, 2026. The filing includes the company’s standard forward‑looking statements caution.

Key Details

• Filing: Form 8-K, dated March 31, 2026 (Item 5.02: Departure of Directors or Certain Officers).
• Notice date: Ms. Jones notified the company on March 27, 2026.
• Effective date: Ms. Jones’ resignation as principal accounting officer is effective April 30, 2026.
• Role: Ms. Jones provided services as an employee of CFGI (an outside service provider) and served as the company’s principal accounting officer.

Why It Matters

• The principal accounting officer plays a key role in the company’s financial reporting and internal controls. Investors should note the announced departure and watch for subsequent filings or disclosures about a successor or transition plan. The company’s 8-K also reiterates standard forward‑looking statement language, reminding investors that outcomes may be affected by risks and uncertainties described in Barinthus’s SEC filings.